Head-to-head evidence
Crexont (IPX203) vs Melevodopa/carbidopa (Sirio)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Parkinson's Disease
Shared mechanism: dopamine precursor · full Parkinson's Disease pipeline
Crexont (IPX203)
Marketed by Amneal Pharmaceuticals
NCT03670953 · Phase 3 · completed
The study was randomized, quadruple-blind, double-dummy, and active-controlled, with 506 participants entering the randomized maintenance period and 495 contributing primary-endpoint data. The clinical primary endpoint was met: IPX203 produced a significantly greater improvement in daily “good on” time than immediate-release carbidopa-levodopa (p=0.0194).
Next expected readout: December 2026 · NCT07138560 (registry estimate)
Melevodopa/carbidopa (Sirio)
Developed by Chiesi Farmaceutici
NCT00491998 · Phase 1/2 · completed
The study was randomized and double-blind, with a planned enrollment of 27 participants and a comparison with standard levodopa/carbidopa tablets. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Crexont (IPX203)'s landscape · Melevodopa/carbidopa (Sirio)'s landscape